# John Rademacher

> John C. Rademacher is president and chief executive officer of Option Care Health and a director of Thrivent. An accounting graduate of Hillsdale College with an MBA from Wayne State University, he joined Option Care as COO in 2015, became permanent CEO in January 2018, and led the combined business after its 2019 BioScrip merger. His tenure also includes the terminated Amedisys agreement in 2023 and the pending acquisition announced by CD&R and McKesson in October 2026.

- **Role:** President and Chief Executive Officer at Option Care Health
- **Organizations:** Option Care Health, Thrivent, Cardinal Health, Cigna, CareAllies, National Home Infusion Association
- **Education:** Bachelor of Arts in Accounting, Hillsdale College, Master of Business Administration, Finance, Wayne State University
- **Known for:** Appointed permanent CEO of Option Care in January 2018 following service as interim CEO., Led the combined company following the 2019 BioScrip merger., During his CEO tenure, Option Care Health reported 2025 net revenue of $5.6495 billion, up 13% year over year.

## Career timeline

- **Before 2015** — Held executive roles at Cigna, including president of CareAllies, and divisional president and general manager roles at Cardinal Health.
- **2015** — Joined Option Care as chief operating officer.
- **2017-08** — Became interim chief executive officer.
- **2018-01** — Named permanent chief executive officer, effective January 4.
- **2019-08** — Became CEO of the combined Option Care Health following the August 6 BioScrip merger; joined its board.
- **2023-05** — Announced agreement to combine with Amedisys.
- **2023-06** — Amedisys agreement terminated; Option Care Health would receive a $106 million termination fee.
- **2026** — Joined Thrivent’s board and its Human Resource & Governance committee.
- **2026-10** — CD&R and McKesson announced a pending acquisition of Option Care Health at $32.05 per share, approximately $5.8 billion enterprise value.

## Achievements

- Appointed permanent CEO of Option Care in January 2018 following service as interim CEO.
- Led the combined company following the 2019 BioScrip merger.
- During his CEO tenure, Option Care Health reported 2025 net revenue of $5.6495 billion, up 13% year over year.
- Joined the Thrivent board in 2026.

## Latest updates

- **2026-10** — October 6: CD&R and McKesson announced an acquisition agreement at $32.05 per share. Expected closing is in the first half of 2027, subject to required approvals; the transaction is pending as of October 21, 2026.
- **2026-08** — August 27: discussed workforce recruitment, retention, training and capacity in an Investment Reports interview.
- **2026-07** — July 29: Option Care Health reported Q2 net revenue of approximately $1.442 billion, up 1.9%, and net income of $53.9 million, up 6.7%.

## Links

- Website: https://optioncarehealth.com
- LinkedIn: https://www.linkedin.com/in/john-c-rademacher

---

Profile page: https://yespress.io/john-rademacher
Published by YesPress — https://yespress.io
Last updated: 2026-10-21